Methylxanthines for the prevention or treatment of intermittent hypoxemia or respiratory insufficiency in late preterm infants

Enrico Bodrero; María Carolina Isaza-López; Adrienne Pahl; Michelle Fiander; Roger Soll; Matteo Bruschettini

doi:10.1002/14651858.CD016113

Methylxanthines for the prevention or treatment of intermittent hypoxemia or respiratory insufficiency in late preterm infants

Cochrane Database Syst Rev. 2024 Nov 20;11(11):CD016113. doi: 10.1002/14651858.CD016113.

Authors

Enrico Bodrero¹, María Carolina Isaza-López², Adrienne Pahl³, Michelle Fiander⁴, Roger Soll⁵, Matteo Bruschettini⁶

Affiliations

¹ Neonatal Intensive Care Unit, S. Croce e Carle Hospital, Cuneo, Italy.
² Materno-Perinatal Care Unit, Bolivarana University Clinic, Medellin, Colombia.
³ Pediatrics, University of Vermont Medical Center, Burlington, VT, USA.
⁴ Cochrane Neonatal Group, Halifax, Canada.
⁵ Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
⁶ Cochrane Sweden, Department of Research, Development, Education and Innovation; Paediatrics, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden, Lund University, Skåne University Hospital, Lund, Sweden.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of methylxanthines in preventing or treating intermittent hypoxemia or respiratory insufficiency in late preterm infants.

Publication types

Systematic Review

MeSH terms

Humans
Hypoxia* / prevention & control
Infant, Newborn
Infant, Premature*
Infant, Premature, Diseases / prevention & control
Randomized Controlled Trials as Topic*
Respiratory Insufficiency* / prevention & control
Respiratory Insufficiency* / therapy
Theophylline / therapeutic use
Xanthines / adverse effects
Xanthines / therapeutic use

Substances

Xanthines
Theophylline